ERBB2 and neoplasm: FASN-related altered lipid metabolism has long been recognized to occur in tumor cell lines with acquired resistance to chemotherapeutics (e.g., doxorubicin, etoposide, cisplatin and paclitaxel) and HER2-targeted therapies (e.g., trastuzumab and lapatinib) [26,27,28,29,30,31,32,33,34,35].